Brain Liquid Biopsy Assay

Creative Biolabs is at the forefront of scientific innovation, continuously striving to develop groundbreaking technologies that advance the field of neuroscience. Our latest cutting-edge service, the Brain Liquid Biopsy Assay, has revolutionized the field of neurological diagnostics. By harnessing the power of circulating tumor cells (CTCs) analysis, brain-derived exosomes analysis, and cfDNA analysis, our Brain Liquid Biopsy Assay service offers unparalleled insights into the complex workings of the brain and opens new avenues for diagnosis, monitoring, and treatment of neurological disorders.

Our Technology

At Creative Biolabs, we have developed a state-of-the-art platform that combines multiple cutting-edge technologies to enable comprehensive analysis of brain-derived biomarkers. By combining these approaches, our assay provides comprehensive insights into the neurological landscape of patients, leading to more accurate diagnoses and improved patient outcomes.

• Circulating Tumor Cells (CTCs) Analysis
  CTCs are rare cells shed by primary brain tumors into the bloodstream. The analysis of CTCs provides valuable information on tumor heterogeneity, enabling personalized treatment strategies and monitoring of treatment efficacy. Once captured and concentrated, these circulating tumor cells (CTCs) can be examined, offering insights into the current state of a disease. Importantly, our liquid biopsy technique is far less invasive for patients compared to the conventional surgical biopsy.

Fig.1 CTCs capture, enrichment, and characterization.¹

• cfDNA & cfRNA Analysis
  Cell-free DNA (cfDNA) refers to the small fragments of DNA that circulate freely in the bloodstream. Our Brain Liquid Biopsy Assay includes the analysis of cfDNA derived from the brain, providing insights into various neurological conditions. By detecting specific genetic alterations, such as mutations or epigenetic modifications, cfDNA analysis can aid in the diagnosis and monitoring of brain tumors, neurodegenerative diseases, and psychiatric disorders.

Fig.2 Liquid biopsy in brain tumor.²

• Brain-Derived Exosomes Analysis
  Exosomes are small vesicles released by cells that contain a wealth of information about their molecular composition. In the context of the brain, brain-derived exosomes (neuronal, astrocyte, and oligodendrocyte origin) offer a unique window into the neurological landscape. Our Brain Liquid Biopsy Assay leverages advanced techniques to isolate and analyze these exosomes, enabling the identification of specific biomarkers associated with neurological disorders, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. This analysis can facilitate early detection, disease progression monitoring, and the development of targeted therapies.

Fig.3 Brain-originated exosomes (neuronal, astrocytic, and oligodendrocytic origin). ³

Highlight

Multi-platform Analysis

These platform technologies may include advanced molecular biology techniques, high-throughput sequencing, next-generation sequencing (NGS), single-cell analysis, and various other cutting-edge methodologies.

Customizability

We offer customized assay design services tailored to meet specific requirements. Our team of experienced scientists collaborates closely with clients to develop assays that target specific biomarkers, optimize sensitivity, and ensure reliable and reproducible results.

Precision

By maintaining strict protocols and standardized procedures, precision ensures that sample analysis data remains consistent and reliable, providing confidence in the results obtained from various locations worldwide.

Please contact us today to explore the potential for collaboration with our organization.

References

1. Yang, Chaogang, et al. "Circulating tumor cells in gastrointestinal cancers: current status and future perspectives." Frontiers in oncology 9 (2019): 1427.
2. Eibl, Robert H., and Markus Schneemann. "Liquid biopsy and primary brain tumors." Cancers 13.21 (2021): 5429.